The Biosimilars Council is proud to partner with the International Generic and Biosimilar Medicines Association (IGBA) to launch a new video, “Biosimilars: A Science Success Story.” This important, informative educational video addresses major topics for stakeholders, including the 10+-years of European experience with biosimilars that have led to more 700 million patient days of safe and efficacious biosimilar use, the underlying science behind originator biologic and biosimilar development and approval, as well as the confidence health care providers can have in prescribing and administering a biosimilar.
Biosimilars: A Science Success Story
About the Biosimilars Council
The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available on our about page.
AAM is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. Generic and biosimilar medicines improve people’s lives, improving society and the economy in turn. AAM represents the manufacturers and distributors of finished generic pharmaceuticals and biosimilars, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 23 percent of total drug spending. Additional information is available at www.accesiblemeds.org.